LOS ANGELES – June 24, 2026 – BioTools Innovator (BTI) VANGUARD has selected five proof-of-concept proposals to receive up to $200K in non-dilutive funding contracts. Through the non-dilutive funding program, BTI VANGUARD aims to support the development and commercialization of innovative enabling technologies that could be readily deployed as medical countermeasures in the event of a health emergency.
BioTools Innovator is the premier accelerator focused exclusively on life science tools and diagnostics startups. VANGUARD is a joint initiative between BTI and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support startups in deploying innovative medical countermeasures that enhance the U.S.’ readiness for public health emergencies.**
Read the Full Article